Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
OXFORD, UNITED KINGDOM, Aug. 03, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Mr Erik Ostrowski, CFO of Summit, will present a corporate overview at the Canaccord Genuity Growth Conference on 9 August 2017 at 10:30am EDT in Boston, Massachusetts, US.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
-END-
For more information, please contact: Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880 N+1 Singer (Broker) Aubrey Powell / Lauren Kettle Tel: +44 (0)20 7496 3000 MacDougall Biomedical Communications (US media contact) Tel: +1 781 235 3060 Karen Sharma [email protected] Consilium Strategic Communications (Financial public relations, UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / [email protected] Jessica Hodgson / Lindsey Neville
